General Information of Drug (ID: DMUX702)

Drug Name
Fibronectin extra domain A Drug Info
Synonyms Fibronectin extra domain A (vaccine adjuvant); Fibronectin extra domain A (vaccine adjuvant), Digna Biotech; TLR-4 antagonist (protein recombinant, vaccination), Digna Biotech/University of Navarra
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
TTD Drug ID
DMUX702

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting Toll-like receptor 4 (TLR4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MPL-containing Pollinex allergy desensitization vaccine DMXSDJU Allergy 4A80-4A85 Preregistration [2]
Cadi-05 DMPTCYB Prostate cancer 2C82.0 Phase 3 [3]
Resatorvid DMFMWYC Sepsis 1G40-1G41 Phase 3 [4]
ERITORAN DMKQZ0L Sepsis 1G40-1G41 Phase 3 [5]
G100 DMKHNXA Non-hodgkin lymphoma 2B33.5 Phase 2 [6]
OM-174 DM2THBX Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
NI-0101 DM31FOP Autoimmune diabetes 5A10 Phase 1 [1]
GSK1795091 DMC6QE4 Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
CRX-675 DMHDSYF Hepatitis virus infection 1E50-1E51 Phase 1 [1]
CS-4771 DMVDLT4 Sepsis 1G40-1G41 Discontinued in Phase 1 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor 4 (TLR4) TTISGCA TLR4_HUMAN Not Available [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
2 Allergy Therapeutics PLC. News Announcement. Allergy Therapeutics. Clinical Trials. Allergy Therapeutics PLC. 11 October 2006.
3 Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
4 Clinical pipeline report, company report or official report of Takeda (2009).
5 Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.
8 Eritoran insight for influenza treatment. SciBX 6(19); doi:10.1038/scibx.2013.453. May 16 2013